导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.88% | 2776/4773 |
| 近一周 | -1.62% | 593/5462 |
| 近一月 | 1.22% | 406/5421 |
| 近一季 | 1.25% | 562/5209 |
| 近半年 | -3.21% | 2148/4920 |
| 近一年 | 1.91% | 2241/4366 |
| 近两年 | 38.45% | 1963/2954 |
| 近三年 | 37.34% | 788/2253 |
| 成立以来 | 145.38% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.28% 3108/4961 |
-5.83% 3628/5312 |
- - |
- - |
| 2025 | 18.73% 2288/4813 |
-0.08% 2051/3635 |
4.75% 703/4076 |
9.64% 3340/4524 |
3.46% 667/4813 |
| 2024 | 24.25% 297/3463 |
9.99% 87/2808 |
1.70% 455/3014 |
13.83% 2096/3129 |
-2.42% 2073/3463 |
| 2023 | -0.65% 463/2656 |
3.14% 1254/2280 |
0.69% 285/2385 |
0.79% 343/2515 |
-5.08% 1253/2655 |
| 2022 | -10.24% 202/2207 |
-5.71% 199/1919 |
1.73% 1430/2016 |
-8.32% 190/2113 |
2.06% 1052/2208 |
| 2021 | 11.92% 393/1822 |
3.05% 199/1255 |
0.64% 1089/1330 |
6.42% 226/1466 |
1.42% 941/1822 |
| 2020 | 27.66% 576/1250 |
-8.58% 621/1028 |
11.42% 732/1067 |
15.59% 206/1164 |
8.42% 672/1184 |
| 2019 | 37.99% 324/1092 |
23.36% 555/754 |
2.28% 93/804 |
1.52% 391/850 |
7.74% 401/918 |
| 2018 | - - |
- - |
- - |
- - |
-12.01% 395/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 中金优选300指数(LOF)A VS. 长安沪深300非周期A(740101) |